- Home
- TALO vs ZLAB Comparison
TALO vs ZLAB Comparison
Compare TALO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALO
- ZLAB
- Stock Information
- Founded
- TALO 2011
- ZLAB 2013
- Country
- TALO United States
- ZLAB China
- Employees
- TALO N/A
- ZLAB N/A
- Industry
- TALO Oil & Gas Production
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- TALO Energy
- ZLAB Health Care
- Exchange
- TALO Nasdaq
- ZLAB Nasdaq
- Market Cap
- TALO 2.0B
- ZLAB 1.8B
- IPO Year
- TALO N/A
- ZLAB 2017
- Fundamental
- Price
- TALO $10.18
- ZLAB $31.38
- Analyst Decision
- TALO Strong Buy
- ZLAB Strong Buy
- Analyst Count
- TALO 10
- ZLAB 4
- Target Price
- TALO $18.25
- ZLAB $52.50
- AVG Volume (30 Days)
- TALO 1.8M
- ZLAB 976.3K
- Earning Date
- TALO 11-04-2024
- ZLAB 11-12-2024
- Dividend Yield
- TALO N/A
- ZLAB N/A
- EPS Growth
- TALO N/A
- ZLAB N/A
- EPS
- TALO N/A
- ZLAB N/A
- Revenue
- TALO $1,744,933,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- TALO $40.71
- ZLAB $48.34
- Revenue Next Year
- TALO $0.54
- ZLAB $47.12
- P/E Ratio
- TALO N/A
- ZLAB N/A
- Revenue Growth
- TALO 24.09
- ZLAB 28.16
- 52 Week Low
- TALO $9.44
- ZLAB $13.48
- 52 Week High
- TALO $15.92
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- TALO 47.36
- ZLAB 70.41
- Support Level
- TALO $9.83
- ZLAB $31.52
- Resistance Level
- TALO $10.66
- ZLAB $36.60
- Average True Range (ATR)
- TALO 0.35
- ZLAB 1.36
- MACD
- TALO 0.03
- ZLAB 0.34
- Stochastic Oscillator
- TALO 46.24
- ZLAB 58.60
About TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.